118 related articles for article (PubMed ID: 3304918)
1. Susceptibility in vitro of gram-positive aerobe and anaerobe bacteria to ofloxacin.
Debbia E; Mannelli S; Gianrossi G; Schito GC
Drugs Exp Clin Res; 1987; 13(4):213-7. PubMed ID: 3304918
[TBL] [Abstract][Full Text] [Related]
2. The sensitivity of gram-negative and gram-positive bacteria to ofloxacin.
Speciale A; Stefani S; Caccamo F; Nicolosi VM; Nicoletti G
Drugs Exp Clin Res; 1987; 13(9):555-61. PubMed ID: 3480796
[TBL] [Abstract][Full Text] [Related]
3. The sensitivity of gram-negative and gram-positive bacteria to ofloxacin.
Speciale A; Stefani S; Caccamo F; Nicolosi VM; Nicoletti G
Chemioterapia; 1987 Feb; 6(1):17-22. PubMed ID: 3470153
[TBL] [Abstract][Full Text] [Related]
4. In vitro activity of pefloxacin against gram-negative and gram-positive bacteria in comparison with other antibiotics.
Debbia E; Schito GC; Nicoletti G; Speciale A
Chemioterapia; 1987 Oct; 6(5):319-23. PubMed ID: 3480779
[TBL] [Abstract][Full Text] [Related]
5. In vitro activity of telavancin against recent Gram-positive clinical isolates: results of the 2004-05 Prospective European Surveillance Initiative.
Draghi DC; Benton BM; Krause KM; Thornsberry C; Pillar C; Sahm DF
J Antimicrob Chemother; 2008 Jul; 62(1):116-21. PubMed ID: 18424792
[TBL] [Abstract][Full Text] [Related]
6. Antimicrobial activity of dalbavancin tested against Gram-positive clinical isolates from Latin American medical centres.
Gales AC; Sader HS; Jones RN
Clin Microbiol Infect; 2005 Feb; 11(2):95-100. PubMed ID: 15679482
[TBL] [Abstract][Full Text] [Related]
7. Doripenem (S-4661), a novel carbapenem: comparative activity against contemporary pathogens including bactericidal action and preliminary in vitro methods evaluations.
Jones RN; Huynh HK; Biedenbach DJ; Fritsche TR; Sader HS
J Antimicrob Chemother; 2004 Jul; 54(1):144-54. PubMed ID: 15190031
[TBL] [Abstract][Full Text] [Related]
8. Activity of nadifloxacin (OPC-7251) and seven other antimicrobial agents against aerobic and anaerobic Gram-positive bacteria isolated from bacterial skin infections.
Nenoff P; Haustein UF; Hittel N
Chemotherapy; 2004 Oct; 50(4):196-201. PubMed ID: 15452398
[TBL] [Abstract][Full Text] [Related]
9. Comparative in vitro activity of CI934, a new fluoroquinolone, alone and in combination with coumermycin, against gram-positive bacteria.
van der Auwera P; Vandermies A; Grenier P; Klastersky J
Drugs Exp Clin Res; 1987; 13(3):125-32. PubMed ID: 3622241
[TBL] [Abstract][Full Text] [Related]
10. In vitro activity of tigecycline against 3989 Gram-negative and Gram-positive clinical isolates from the United States Tigecycline Evaluation and Surveillance Trial (TEST Program; 2004).
Bouchillon SK; Hoban DJ; Johnson BM; Johnson JL; Hsiung A; Dowzicky MJ;
Diagn Microbiol Infect Dis; 2005 Jul; 52(3):173-9. PubMed ID: 16105561
[TBL] [Abstract][Full Text] [Related]
11. Potency and spectrum trends for cefepime tested against 65746 clinical bacterial isolates collected in North American medical centers: results from the SENTRY Antimicrobial Surveillance Program (1998-2003).
Sader HS; Fritsche TR; Jones RN
Diagn Microbiol Infect Dis; 2005 Jul; 52(3):265-73. PubMed ID: 16105569
[TBL] [Abstract][Full Text] [Related]
12. Comparisons of parenteral broad-spectrum cephalosporins tested against bacterial isolates from pediatric patients: report from the SENTRY Antimicrobial Surveillance Program (1998-2004).
Jones RN; Sader HS; Fritsche TR; Pottumarthy S
Diagn Microbiol Infect Dis; 2007 Jan; 57(1):109-16. PubMed ID: 16930923
[TBL] [Abstract][Full Text] [Related]
13. Comparative in vitro activities of daptomycin, linezolid, and quinupristin/dalfopristin against Gram-positive bacterial isolates from a large cancer center.
Smith PF; Booker BM; Ogundele AB; Kelchin P
Diagn Microbiol Infect Dis; 2005 Jul; 52(3):255-9. PubMed ID: 15935606
[TBL] [Abstract][Full Text] [Related]
14. Daptomycin antimicrobial activity tested against methicillin-resistant staphylococci and vancomycin-resistant enterococci isolated in European medical centers (2005).
Sader HS; Watters AA; Fritsche TR; Jones RN
BMC Infect Dis; 2007 Apr; 7():29. PubMed ID: 17442104
[TBL] [Abstract][Full Text] [Related]
15. In vitro study of the antibacterial activity of ofloxacin against recent clinical isolates.
Varoli O; Ferri M
Drugs Exp Clin Res; 1987; 13(4):209-12. PubMed ID: 3476290
[TBL] [Abstract][Full Text] [Related]
16. Comparative activity of garenoxacin and other agents by susceptibility and time-kill testing against Staphylococcus aureus, Streptococcus pyogenes and respiratory pathogens.
Noviello S; Ianniello F; Leone S; Esposito S
J Antimicrob Chemother; 2003 Nov; 52(5):869-72. PubMed ID: 14519672
[TBL] [Abstract][Full Text] [Related]
17. Comparison of ciprofloxacin and ofloxacin using human corneal susceptibility levels.
Kowalski RP; Karenchak LM; Gordon YJ
Cornea; 1998 May; 17(3):282-7. PubMed ID: 9603384
[TBL] [Abstract][Full Text] [Related]
18. Antimicrobial susceptibility of Gram-positive bacterial isolates from the Asia-Pacific region and an in vitro evaluation of the bactericidal activity of daptomycin, vancomycin, and teicoplanin: a SENTRY Program Report (2003-2004).
Biedenbach DJ; Bell JM; Sader HS; Fritsche TR; Jones RN; Turnidge JD
Int J Antimicrob Agents; 2007 Aug; 30(2):143-9. PubMed ID: 17531446
[TBL] [Abstract][Full Text] [Related]
19. In vitro activity of levofloxacin against gram-positive bacteria.
Montanari MP; Mingoia M; Marchetti F; Varaldo PE
Chemotherapy; 1999; 45(6):411-7. PubMed ID: 10567771
[TBL] [Abstract][Full Text] [Related]
20. [In vitro antibiotic susceptibility of staphylococci].
Baykal M; Akalin HE
Mikrobiyol Bul; 1989 Apr; 23(2):157-62. PubMed ID: 2626105
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
